EUVIMEDEUVIMED entdecken
Crossref

Dapagliflozin ameliorates diabetic kidney disease by inhibiting oxidative stress and AIM2-dependent pyroptosis via SIRT1 activation

Hao Wang, Chunliu Li, Xiao Wang, Feng Yan, Bihan Li, Jiahui Gao, Kuo Zhang, Jiahong Wang

Biochemical Pharmacology · 2026-09 · 251 · 118200

DOI: 10.1016/j.bcp.2026.118200 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026-09. Verfasst von Hao Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Clinical Pharmacy, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang 110016, China. Hauptthemen laut MEDLINE: Glucosides, Sirtuin 1, Benzhydryl Compounds, Oxidative Stress. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Shenyang Pharmaceutical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic kidney disease (DKD), a predominant microvascular complication of diabetes mellitus, still lacks curative therapies to completely halt its progressive deterioration. Our study investigated the renoprotective mechanisms of dapagliflozin (dapa) in DKD. Through bioinformatic analysis of clinical DKD datasets, preclinical in vivo and in vitro assays, we identified absent in melanoma 2 (AIM2) as a critical pyroptosis-associated gene upregulated in DKD. In silico structure-based validation revealed that dapa stably binds to the catalytic domain of silent information regulator 1 (SIRT1) via key residues GLN-361 and SER-365, suggesting its potential to modulate SIRT1 deacetylase function. Gain- and loss-of-function assays confirmed that SIRT1 is the core functional target of dapa: dapa upregulated SIRT1 protein expression to inhibit nuclear factor-κB (NF-κB) signaling, thereby blocking AIM2 inflammasome-mediated renal tubular pyroptosis and oxidative damage. These findings reveal a previously unreported mechanism by which dapa regulates SIRT1/NF-κB/AIM2 signaling to exert renoprotection, and provide promising therapeutic targets for the clinical management of DKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosidesSirtuin 1Benzhydryl CompoundsOxidative StressDiabetic NephropathiesPyroptosisSodium-Glucose Transporter 2 InhibitorsAnimalsHumansMiceMaleMice, Inbred C57BLDiabetes Mellitus, ExperimentalEnzyme Activation

Stichwörter der Autor:innen

AIM2DapagliflozinDiabetic kidney diseaseOxidative stressPyroptosisSIRT1

Substanzen

GlucosidesSirtuin 1Benzhydryl CompoundsdapagliflozinSirt1 protein, mouseSIRT1 protein, humanSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • School of Clinical Pharmacy, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang 110016, China.
  • School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang 110016, China.
  • School of Clinical Pharmacy, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang 110016, China. Electronic address: kzhangchn@163.com.
  • School of Clinical Pharmacy, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang 110016, China. Electronic address: wangjiahong@syphu.edu.cn.

Förderung

  • Shenyang Pharmaceutical University

Zitieren

APA

Wang, H., Li, C., Wang, X., Yan, F., Li, B., Gao, J., Zhang, K., & Wang, J. (2026). Dapagliflozin ameliorates diabetic kidney disease by inhibiting oxidative stress and AIM2-dependent pyroptosis via SIRT1 activation. Biochemical Pharmacology, 251, 118200. https://doi.org/10.1016/j.bcp.2026.118200

Vancouver

Wang H, Li C, Wang X, Yan F, Li B, Gao J, et al. Dapagliflozin ameliorates diabetic kidney disease by inhibiting oxidative stress and AIM2-dependent pyroptosis via SIRT1 activation. Biochemical Pharmacology. 2026;251:118200. doi:10.1016/j.bcp.2026.118200

BibTeX
@article{Wang2026,
  author = {Wang, Hao and Li, Chunliu and Wang, Xiao and Yan, Feng and Li, Bihan and Gao, Jiahui and Zhang, Kuo and Wang, Jiahong},
  title = {Dapagliflozin ameliorates diabetic kidney disease by inhibiting oxidative stress and AIM2-dependent pyroptosis via SIRT1 activation},
  journal = {Biochemical Pharmacology},
  year = {2026},
  volume = {251},
  pages = {118200},
  doi = {10.1016/j.bcp.2026.118200}
}
Kostenlos starten →